CA1188988A - Chondroitin drug complexes - Google Patents
Chondroitin drug complexesInfo
- Publication number
- CA1188988A CA1188988A CA000406418A CA406418A CA1188988A CA 1188988 A CA1188988 A CA 1188988A CA 000406418 A CA000406418 A CA 000406418A CA 406418 A CA406418 A CA 406418A CA 1188988 A CA1188988 A CA 1188988A
- Authority
- CA
- Canada
- Prior art keywords
- chloramphenicol
- chondroitin
- sulfate
- process according
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
Abstract
Abstract A chondroitin or a chondroitin sulfate covalently or ionically bonded to a drug substance to form a prodrug which, when injected into animal tissue, undergoes natural conversion in the physiological environment to provide controlled release of the drug or an active drug complex.
Description
G~ycosamino~lxcan ~rug Complexes Many clinical situations exist in which it is advisable~ sometimes necessaryf to administer a drug in a controlled manner such that the concentration in the tissues of the patient is hi~h enough to be effectiv2 but not so high as to cause toxic or other undesirable side effects. The rate of drug release can be control~ed in a variety o~ waysy such as by encapsulation in a material which dissolves slowly in the body fluids, by entrapment in a bolus or matrix ; 10 from which the drug diffuses slowly, or by con~ersion : into a so-called "prodrug~" in which the drug is bound with another substance into a substantially inactive compound or complex and is gradually released by physiological action when injected into the tissues of the patient.
The present invention relates to a novel class of prodrugs in which the drug substance is bonded ionically or covalently to a glycosaminoglycan of the class of the chondroitin~, and to the use of such prodrugs in the treatment of animal and human patients.
Danishefsky and Siskovic~ Carbohydrate . Research, 16, 199 (1971), while studyiny the s~ructure-function implication of the glycosaminoglycans, found that the amino function of certain amino acids can be ~.
covalently linked to the carboxyl group of a glycosaminoglycan. ThiS is, of cour~se, a conventional amidation; and while a similar reaction is employed in making some of the substances of the present invention~
Danishefsky and Siskovic did not make, or suggest the possibility of making, a prodrug.
Mill et al U.S. Patent 4~003,792 teaches that proteins may be bound to acid polysaccharides of plant origin, specifically alginic acid, pectic acid, celluronic acid, and carageenan~ Such polysaccharides are food carbohydrates, alien to the blood and tissues of anlmals, and are clearly distinct both chemically and physiologically from the chondroitins used in the present invention. While Mill et al indicate that their complexes may ~e used for preparing antisera and for slow release of antisera, they do not describe how slow release of antisera can be achieved. In contrast, the chondroitin complexes of the present invention are compatible with animal blood and tissue and are normally cleaved by body metabolism to release the active drug.
Yannas and Burke U.S. Patents 4,060,081 and 4,059~572 use the ionic properties of mucopolysaccharides (an older term essentially coextensive with th~ glycosaminoglycans) to flocculate or complex ionically with proteins. For example, an artificial skin formulation was prepared from chondroitin sulfate and collagen.
Heparin (a glycosaminoylycan) is very effective in slowing the clotting of blood, but is relatively short-acting when administered. A variety of derivatives have therefore been made to delay its absorption and prolong its pharmacological action.
Thus, Mardiguian and Fournier UOS~ Patent 3~835~112 esterifies the hydroxyl groups of heparin with long chain fatty acids to give insoluble complexes which slowly re-generate the ac-tive soluble heparin upon cleavage o~ the ester bond. Bernasconi et al (G~ Ital. Chemioter., 3, 79 (1956)) react heparin with tetracycline to produce a slowly soluble salt complex with a prolonged payout of heparin.
Laland Norwegian Patent 97,467 (1961) prepares a long-acting salt of adrenocorticotropic hormone (ACTH) and hyaluronic acid. The latter, a mammalian polyuronide, is a non-sulfated ; glycosaminoglycan, and perhaps for this reason -the complex shows no autocatalytic effect and no significant amount of fast hydrolysis.
The advantages of using the chondroitins in the preparation of prodrugs lie in the fact that such molecules are found throughout the body, are biocompa-tible, are not species-dependent, and are metabolically cleaved from the drug substance in pro-longed periods ranging from days to months.
In accordance with the present invention, a chondroitin is reacted in a known manner with a drug substance as hereinafter defined to produce a derivative which, upon injection into the body in the form of a solution or finely divided suspenslon, is metabolically decomposed to release the drug or a drug complex in therapeutically active form. The drug substance i.s released from the carrier by hydrolysis of the attachment bond in the case of covalently linked prodrugs, either by body fluids or by enzymes, or is released by enzymatic degrada-tion of the chondroitin matrix, or both; or by gradual ionization in the case of ionically linked prodrugs.
'~3~
,, . - 3a -According -to one aspect of the present invention there is provided a process for preparing a prodrug having chloramphen-icol, methotrexate, adriamycin, vinblastine, vincristine, vindesine, 6-mercaptopurine, 5-fluorouxacil, a penicillin antibiotic, a cephalosporin antibiotic, or a l-oxacephalosporin antibiotic as a pharmaceutically active constituent, which comprises esterifying, amidating, or ionically bonding said pharmaceutically active constituent or a reactive derivative thereof, with chondroitin-4-sulfate or chondroitin-6-sulfa-te, or a reactive derivative thereof, the prodrug having the property, when injected into animal tissue, of undergoing na-tural con-version in the physiological environment to provide a controlled release of said pharmaceutically ac-tive constituent or pharm-aceutically active complex thereof.
According to another aspect of the present invention there is provicled the prodrug product of the above process.
The repeating struc~ural unit of -the chondroitins is shown in the drawing. In the basic chondroitin struc-ture, both Q and R are hydroxyl. The 81~
chondroitins occur most commonly in one of ~wo forms, chondroitin-4-sulfate ~"C4S"), in which the hydroxyl at Q is sulfated, and chondroitin-6-sulfate ("C6S"), in which the hydroxyl at R is sulfated~ These substances are water-soluble; and depending upon the drug loading and the nature of the drug complex~ the prodrug product may be formulated as an aqueous solution or an aqueous colloidal suspension for injection into the patient.
As will be seen from the drawing, a variety of functional groups are availabl~ in the chondroitins for covalent bonding (particularly carboxyl, COOH/ and hydroxyl, 0~) and for ionic bonding tsulfate -OS03-, and carboxylate~ -COO~) with drugs. Covalent bonding can be by way of ester links, -COOY, or amide links, -CONHY, either directly to an appropriate functional group of the drug or by way of a bio~acceptable linking substance, e.g., an amino acid or ureaO Thus, drugs having the general formula X-Yn are suitable for use in the present invention, where X
; is or can be converted into a carboxyl, hydroxyl, sulfydryl, or amino function; n is an integer at least l; Y is the residue of the drug molecule -- i.e., its characteristic structllre exclusive of the reactive function X; and Y, when plural, may be the same or different groups. Illustrative ~rugs include pencillin G, pencillin V, ampicillin, carbenicillin, and the whole range of penicillin antibiotics, both natural and synthetic; cephalothin, cephaloridine, cephaloglycin, cephalexin, cephradine, cefa~olin, cefamandole, cefaclor, and the whole range of cephalosporin antibiotics, including the l-oxa, l-aza, and l-carbo analogues thereof; chloramphenicol; adriamycin (daunorubicin); methotrexate; vinblastine, vincristine, vindesine; 6-mercaptopurine; 5-fluorouracil; and the like.
Linking substances typically have the general formula Rl- Z_R2 where Rl~and R2 are or can be converted into carboxyl, hydroxyl, sulfhydryl, and amino functions and may be the : same ~r di~ferent, and where Z is an organic group~ the whole substance being bio-acceptable -- i,e., having no objectionable toxicity or pharmaceutical activity incompatible with the drug substance. Illustrative linking substances include urea, guanidine, glycineF
alanine, phenylalanine~ lysine, aspartic acid, glutamic acid, trimethylene glycol, 6-aminocaproic acid, thioglycQlic acid, an~ the like.
The reaction of the chondroitin with the drug substance to obtain the novel substances of the present invention is carried out in a known manner, depending upon the functional groups involved.
Where the chondroitin and the dru~ substance contain a hydroxyl group and a carboxyl group, respectively, the two can be reacted by use of a carbodiimide; or the carboxyl group can be converted to an acid chloride and reacted with the hydroxyl group; or the carboxyl group can be conver~ed to a mixed anhydride and reacted with the hydroxyl group. All of these procedures and the conditions required therein are old and well known in the ar~. The same procedures can be used when the chondroitin and the drug substance contain a carboxyl group and a hydroxyl groupl respectively. In all cases, the product is an ester. Sulfhydryl groups may be reacted in a manner analogous to hydroxyl groups.
When the chondroitin and the drug substance contain a hydroxyl and an amino group, respectively ~or vice versa3, the reaction can be caused to proceed through ormation of a carbamate bond via the activation of the hydroxyl to a chloroformate moiety with subsequent linking to the amine function. The procedure and proper reaction conditions are well known and conventional in the art. Similarly, a carbonate bond may be formed between two hydroxyl groups (on the chondroitin and on the drug~
When the chondroitin and the drug substance contain a carboxyl group and an amino group, respectively (or vice versa~, the reaction is one of conventional amide formation under known conditions employing known procedures~ eliminating a molecule of water between the two molecules~ Alternatively in such a case, the two substances may be reacted ionically in the presence of water to form a pro~uct in the nature of an ammonium salt. In the same way~ an acid sulfate or an acid sulfonate can be reacted with an amine to form a salt. The amine function of methotrexate~ for example~
can be converted to the quaternary ammonium form and subsequently complexed ionically with a chondroitin acidic function. Where one or both of the starting materials contains more than one functional group, it may be desirable to protect groups that are not desired to react, in order to avoid obtaining a mlxed product.
These are techniques which are well known in the artO
Linking molecules can convenien$1y be employed when the chondroitin and the drug substance do not contain mutually reactive functional ~roups -- for example~ when both contain carboxyl and neither contains primary aminoS NH~. In such a case, any substance can be employed as a linking agent which has two functional groupsy one capable of reacting with the chondroitin, the other with the drug. To link carboxyl groups, for examplet it is convenient to employ ure~, guanidine, or a bio-acceptable diamine such as ethylenediamine or trimethylenediamine~ reacted first with the chondroitin~
then with the drug substance, or vice versar Linking molecules can also be employed to overcome ~teric or other chemical problems in a given case.
The reaction products of the present invention are conveniently prepared for administration by dissolving in ~ater or in an isotonic salt solution~ or, in cases where the product is less soluble ~ by comminuting and suspending in water or an isotonic salt solution. In ~he la~ter case, the product can also be dissolved in an appropriate organic solvent such as 10 dimethylsulfoxide, dimethylformamide, or the like~
diluted with water to form a colloidal suspension, and vacuum stripped or dialyzed against water to remove the organic solvent. The solution or suspension may appropriately contain from about 5 to about 500 mg. of product per milliter as a suitable concentration for injection into the patient, and the volume injected is chosen to provide the desired drug dosage which will~ of course, vary with the drug substance.
We have found that the rates of hydrolysis of C4S and C6S drug complexes are similar for a given druy and loading, and exhiblt a significant initial amount of fast hydrolysis, even at low loading -- an effect not seen with compounds lacking the sulfate moiety. It is thus considered that the sulfates play a major role in the autocatalytic hydrolysis of C4S and C6S drug complexes.
The invention is illustrated by the fv].lowing ~pecific examples:
C4S~Chlora~ henicol Ester via C4S Acid Chloride To an anhydrous solution of the free acid o chondroitin-4-sulfate (C4S; 155.5 m5t prepared by ion exchange) and pyridine t0~2 ml) .in dimethylformamide R~
tDMF, 35 ml) is added a solution of thionyl chloride (46.5 mg3) in dimethylformamide (1 ml), and the mixture is stîrred at 60C for 20 minutes. To the resulting solution of C4S acid chloride is added a solution of chloramphenicol ~101.3 mg) in DMF ~2 ml) and stirrlng is continued for 21 hours at room temperature. The C4S-chloramphenicol ester prodrug product is then recovered by neutralizing the reac~.ion mixture with dilu~e sodium hydroxide, dialyzi~g extensively against water, and lyophilizing, yielding 172~8 mg of the C4S chloramphenicol ester prodrug.
15C6S-Chloramphenicol Ester via C6S Acid_Chloride In the same way~ the chonodroitin~6-sulfate ~C6Sj chloramphenicol ester prodrug is prepared by reaction of the free acid of C6S (40.5 mg), pyridine 20 (Ool ml), anhydrous dimethylsulfoxide (DMS0, 8.5 ml), thionyl chloride (3.7 mg in 0~8 ml DMF), and chloramphenicol (2008 mg in 1 ml DMF), yielding 22.4 mg of purified e~ter prodrug.
25EX~MPLE 3 C4S-Chloramphenicol Ester via C4S Mixed Anhydride To an anhydrous solution of the free acid of C4S (51.4 mg) in DMF (11 ml) is added pyridine (0.1 ml) and isobutyl chloroformate (ll.D mg in 0.75 ml D~), and the mixture is allowed to react at 0C for 20 minutes.
To the resulting solution of C4S mi~ed anhydride is added a solution of chloramphenicol (27.1 mg in 1 ml DMF) and stirring is continued for 15 minutes at 0C, then 12 hours at room temperatureO The product is isolated ~;
9 _ as in Example 1 by neu~raliæa~ion/dialysis/lyophllizatlon, yielding 49~1 mg of e~ter prodrug.
C6S-Chlor~phenicol Ester _ _ via C6S Mixed_Anhydride The ~5S-~hloramphenicol ester product is prepared according to the procedure of Example 3 by reacting C6S (40~5 mg) in DMS0 t8 ml) with isobutyl chloroforma~e (8.7 mg in 0.8 ml DMS03, pyridine (0.1 ml)~ and chloramphenicol (20~8 mg in 1 ml DM~).
Isolation as in .Example 1 yields 19.0 mg o C6S-chloramphenicol e~ter prodrug.
_XAMPLE 5 C4S Methotrexate Amide via Carbodiimide To a 501ution of C4S (10 mg) and methotrexate dimethyl ester trihydrochloride (12 mg) in a 1~1 D~F/H20 solution (3 ml) under nitrogen is added l-ethyl-3,3 dimethylaminopropyl carbodiimide ~EDC, 6 mg).
From the reaction product~ worked up as in Example 1, is recovered 14.1 mg of the C4S-methotrexate amide prodrugO
2S EXAMPL~ 6 C4S-Adr~ cin Amide _ via Carhodiimide To a 1:1 ~volume) mixture of DMF and water (1 ml) at pH 2 containing the fxee acid of C4S (5~1 mg) 30 is added adriamycin (5 mg) in 1:1 DMF/H~0 (1 ml3 with stirring. l-Ethyl-3~3-dimethylaminopropyl carbodiimide ~EDC, 3 mg) in water (0.5 ml) is then added at room temperature with .stirxing~ during which the pH of the mixture rises to 3.75. After 24 hours, the reaction product is neutralized with sodium bicarbonate, dialyzed extensively against water, and lyophilized. The C4S adriamycin amide prodrug is obtained as 6.5 mg of pure material.
C6$~Chlor~henicol Ester via Carbodiimide A solution of C6S (6809 mg) in water (5 ml) is added to a solution of chloramphenicol ~45~3 mg) in DMF (5 ml) and the pH is ad justed to 4 . 75 with dilu~e HCl. EDC (26.2 mg~ is added and the pH kept at 4 0 75 Eor one hour at room temperature. Workup as in Example 6 y;elds 33.7 mg of c6s~Ghloramphenicol ester prodrug~
C4S--Chloramph~nicol Est r via Carbodiimide A solution of the free acid of C4S (123~5 mg) 20 in anhydrous DMF (1.5 ml) is added to a DMF solution (0.2 ml) containing chloramphenicol (22.7 mg) and 4-pyrrolidinopyridine (4-PP, 18.5 mg) acylation catalystr follwed by dicyclohexyl-carbodiimide (DCC, 13. 5 mg~ in DMF (0. 2 ml), and held at -8C :Eor 36 hours.
The insoluble dîcyclohexylurea by-product is filtered of and discarded. To the filtrate is added 3 volumes of ether. The precipitate is filtered off, washed with ether and air dried, then redissolved in the minimum amoun~ (0.2 ml) of sodium phosphate buffer ~lM~ pH=7)~
The solid is precipitat~d again~ this time with 3 volumes of ethanol~ and washed with ether. The solid is again dissolved in phosphate buffer an~ reprecipitated as above. After a final ether wash and air drying~ a yield of 110.4 mg of pure C4S chloramphenicol ester 35 prodrug is obtainedO
EXAMPL~ 9 C6S-Chloram~henicol ~ster ia Acid Ca~alysis A portion of the free acid of C6S (50.2 mg) is placed in a vacuum oven over P2O5 at 110C overnight to remove water of hydration. The ~otal weight loss is lZ.5 mg. The dried material is dissolved in ~nhydrous dimethyl sulfoxide (DMSO, 3 ml) together with chloramphenicol (94,0 mg~ and trifluoracetic acid (0.01 ml) to serve as an acid catalyst. ~he mixture is stirred at 80C for 20 hours, then worked up as in Example 1. A yield of 16D 4 mg of C6S-chloramphenicol ester prodrug is ohtained.
A carboxyl function of a chondroitin can be esterified to an intermediate moiety possessing an alcohol function~ for example ethanol, and the chondroi.tîn-ethyl ester can then be transesterified with a hydroxyl group of a drug or an intermediate linking group under acidic conditions. These methods are illustrated in the two following examples.
EXAMPLE 10 .
C4S-Chloramph~nicol Ester by Transe~t~ _ The ethyl ester of C4S is made by the ~ollowing method~ C4S (1~09~ g] is suspended in anhydrous DMF ~50 ml) at 60 Cr and ethyl iodide ~2~5 ml, recently distilled) is added. Stirring is continued for 4 days at 60C, after which the suspension is filtered, the residue washed twice with ether, redissolved in phosphate bufer (lM~ pH=7~ r and, precipitated from 3 volumes of ethanol. The .resulting pellet is washed with ether, redissolved in water, and . reprecipitated from ethanol to yield 0.958 g of the ethyl ester of C4So Transesterification of the ethyl ester of C4S
by a hydroxyl function of chloramphenicol is accomplished by adding the ethyl ester of C4S as produced above (57.0 mg) to chloramphenicol (20.2 mg) and trifluoracetic acid (0~001 ml) in anhydrous DMF
(5 ml). After 4 days at 60Cv ~he product is filtPred and worked up in Example 1, yielding 43~2 mg of the ester prodrug o chloramphenicol and C4S.
EX~MPLE 11 ~4S-Chlor~phenicol Ester by Transesterification An alternative route of making C4S-ethyl ester is to dissolve the free acid of C4S (60~1 mg) in anhydrous DMF ~5 ml) and then add DCC (2509 mg) in DME' (0.3 ml~ followed after 10 minutes by sodium ethoxide (29.3 mg). Stirring at room temperature for 18 hours produces a viscous solution. The product is i501 ated by removal o DMF (40C in vacuo) and trituration in ether;
yield, 65~0 mg of the ethyl ester of C4S.
Transesterification of the C4S ethyl ester with a hydroxyl function of chloramphenicol is carried out by dissolving the C4S ethyl ester (58,1 mg), chloramphenicol (20.2 mg), and trifluoroacetic acid (0.001 ml~ in anhydrous DMF (5 ml)~ Stir.ring at 60C
for 4 days and working up the reaction product mixture as in Example 1 yields 34.~ mg o C4S-chloramphenicol ester prodrug~
C4S-Me~hotrexate Ester via Transesterification The hydroxyl groups of a chondroitin can be used in a transesterification reactîon with an ester function of a drug to yield the acylated chondroltin, ;
i.~., ~he chondroitin es~er prodrug. For example~ a hydroxyl function of C4S can be reacted with the dimethyl ester trihydrochloride of methokrexate to yield an ester-linked C4S-methotrexate prodrug according to the following procedure.
To a solutlon of the free acid of C4S
(41.6 mg) in anhydrous DM~ ~10 ml) is added methotrexate dimethyl ester trihydrochloride (2707 mg) and trifluoracetic acid (0.001 ml) as acid catalyst.
Stirring at 60C for 7 days under anhydrous conditions and product isolation as in Example 1 yields 35.4 mg of the C4S-methotrexate ester prodrug.
The hydroxyl functions of a chondroitin can be caused to react with an activated carboxyl group of a drug or an intermediate linking substance to produce an ester bond. Activation of the molecule to be attached to the chondroitin is achieved by well-known standard methods such as by conversion to the acid chloride or mixed anhydride, by use of carbodiimide, or by use of acid catalyzed transesterification methods. These procedures will be elucidated in th~ following two examples.
C4S-Penicillin V Ester via Mixed Anhydride The carboxyl group of phenoxymethyl penicillin (penicillin V) is ester-linked to the hydroxyl gr3up of C4S by `the following mixed annhydride procedure.
Penicillin V free acid ~3.04 9~ is dissolved in a cold (5C) mixture of DMF (50 ~1) and pyridine (0.80 g), and isobutyl chloroformate (1.19 g~ is added with stirring.
The mixture is held at ~10c with stirring for 30 minutesO The mixed anhydride reaction product is not isola~ed, but is added ~ se to a solution of the ~ree acid o~ C4S ~1.48 g) in DMF at room ~emperature. After stirring for 6 hours, the C4S~penicillin V est2r prodrug is precipitated from solution with an excess of ether J
iltered, neutralized with dilute sodium hydroxide~ and lyophilized. The yield is 1~14 g of purified product~
While the ahove scheme employs a mixed anhydride, a symmetrical anhydride can also be used;
i.e., by converting penicillin V into its symmetrical anhydricle in a known manner.
C4S-Penicillin V Ester via Carbodiimide The reaction of the carboxyl group of penicillin V free acid with a hydroxyl group of C4S can be carried out directly by use of a carbodiimid~
according to the following procedure. Penicillin V free acid (1.41 g) and EDC (0.64 g) are dissolved in anhydrous DMF (50 ml~ and added to a solution of C4S
20 free acid (1.79 9) and pyridine ~1.5 ml) in DMF
(180 ml), after which the mixtue is stirred and held at room temperature for six hours~ The product is isolated as described in Example 13, yielding 1.41 g nf the C4S-penicillin V ester prodrug~
The ionic (acidic) nature of the chondro.it.ins can be used to form ionic complexes (salts) with drugs or with drugs attached to an intermediate linkiny molecule that is basic or can be made basic. The following three examples illustrate this concept.
: EXAMPLE 15 C4S-Adriam~cin Ionic Complex An aqueous solution (1 ml) of the sodium salt of C4S (5.1 mg) is dropped into an aqueous solution (1 ml) of the hydrochloric acid ~alt of adriamycin (6 mg). The mixture is stirred at room temperature for 24 hours and subseauently neutralized with a solution of sodium bicarbonate, dialyzed extens;vely ag~inst water~
and lyophilizedO Obtained is 8.8 mg of the ; C4S-adriamycin ionic complexO
C6S-Alanine-Chlorampherlicol ~
Drugs which do not include a basic moiety (e,g., a quaternary ammonium group) may be derivatized in such a way as to introduce a basic function to complex with the acidic function of a chondroitin to produce an ionic complex. Illustrative of this is the derivati~ation of the hydroxyl groups of chloramphenicol with the carboxyl group of an intermediate linking group, alanine, to orm an e5terO The ammonium ~unction of the alanine-chloramphenicol ester is then complexed with a chondroitin to make a polymeric prodrug salt.
The alanine-chloramphenicol ester is synthesized by dissolving chloramphenicol (12.906 g);
: N-carbobenzoxy-L-alanine ~lOo 003 9) ~ and 4-pyrrolidinopyridine ~0.597 g) in anhydrous tetrahydro~uran (THF, 30 ml3. A solution of dicyclohexylcarbodiimide (DCC 8.660 g) in T~F ~15 ml) is added dropwi5e to the above with stirring at room temperature. After 17 hours, the insoluble dicyclohexylurea by-product is filtered o~E and th~
30 ~olvent stripped o$ ln vacuo at 40C to yield a yellow oil. The oil is taken up in dichloromethane ~300 ml~ and extracted successively with three 2Q0 ml portions of each of the following in the order namedo saline~ 5%acetic acid in saline, saturated sodium bicarbonate, and saline. The organic layer is dried over anyhdrous maynesium sulfate and concentrated to about 20 ml. Addition of 3~% ~Br in acetic acid (40 ml~
to this solution under anhydrous conditions at room temperature over a period of 2 hours removes the protective group from the amino function of the alanine~
A large excess ~450 ml) of anhydrous ethyl ether is added to the solution, causing the hydrobromide salt of the alanine-chloramphenicol ester to precipitate outO
Decanting and trituration in ether followed by recrystallization from anhydrous DMF/ether yields 18~693 g of the salt as a hygroscopic wbite powder~
The hydrobromide salt of the al~nine-chloramphenicol ester produced above ~44.8 mg3 in water (0.5 ml) is added dropwise to a stirred aqueous ~1 ml) solution of C65 (29.9 mg) at room temperatureO After 4 hours, the mixture is worked up as in Example 1 to yield 38~7 mg of the C6S-alanine~chloramphenicol prodrug.
C4S-Alanine-ChloramRhenicol onic Complex Reaction of C4S (29.8 mg) and alanine-chloramphenicol hydrobromide (44.5 mg) according to the procedure oE Example 16 yields 35.2 mg of the C4S-alanine-chloramphenicol prodrug.
C~S-Urea-Penicillin V
The carboxyl group of penicillin V is amide-linked to a glycosaminoglycan through the amine function of urea as an intermediate linking molecule according to the following procedure. C4S (8210 5 mg~
and urea (757.8 mg) are dissolved in water (15 ml) at p~ 4.75. EDC ~434.9 mg~ is added and the p~ kept at 4.75 for 5 hours at ro~m temperature~ The C4S urea amide-linked intermediate is isolated by dialysis and lyophilization. A portion of the C4S-urea (251.5 mg) and penicillin V potassium sal~ (410~5 mg~ are dissolved in water (15 ml) and the p~ is adjusted to 6Ø EDC
~20900 mg) is added and the same pH maintained for 5 hours, after which the mixture is worked up as in Example 1, yielding the C4S-urea-pencillin V prodrug.
EXAMPLÆ 19 C6S-6-Aminocaproic Acid~Chloramphenicol Long-chain linking molecules containing appropriate functional groups on both ends of the molecule are especially useful in linking a drug with a chondroitin when the poin~ of a~achment on the drug is sterically hinaered. Drug and linkex may be attached in high yield, followed by reaction with the chondroitin.
As an example of such a linker, 6-aminocaproic ~cid is attached to chloramphenicol in the same manner as alanine (Example 161. N-carbobenzoxy-6-aminocaproic acid (550.1 mg), chloramphenicol (54B.7 mg), and 4~pyrrolidinopyridine (25.4 mg) in dry THF (10 ml) are reacted with-DCC- (394.4 mg) in dry THF (2 ml); .and after 16 hours at rvom temperature and purification as in Example 16, the oil obtained is reacted with 30%
HBr/acetic acid (5 ml1 at room temperature for 1 hour.
Further purification as before yields 38~.0 mq of the ester-linked chloramphenicol-6-aminocaproic acid hydrobromide.
The hydrobromide product thus obtained (292.'~ mg) and the sodium salt of C6S (15~.9 mg) are ~ 30 dissolved in 2~1 DMF/water (2.5 ml) and the pH is ; adjusted to 4.75~ A solution of EDC (125~2 mg) in 2:1 ~ DMF/water ~005 ml) is added slowly and the p~ kept at ; 4.75 for three hours with stirring at room te~peratureO
Purification is carried out as in Example 1 to ~ield ~- ~8 ~
189.4 mg of the chloramphenicol-6-aminocaproic acid-C6S
prodrug.
6S-Alanine 14C~Chloram~henicol Chloramphenicoll radio-labelled with 14C at both of its dichloroacetyl functions~ is amide-linked through alanine to C6S by the following procedure~
generally paralleling Example 16.
The sodium salt of C6S l3-024 g~ and the radio labelled 14C-chloramphenicol~alanine hydrohromide (prepared as in Example 16 7 5.173 9) are dissolved in
The present invention relates to a novel class of prodrugs in which the drug substance is bonded ionically or covalently to a glycosaminoglycan of the class of the chondroitin~, and to the use of such prodrugs in the treatment of animal and human patients.
Danishefsky and Siskovic~ Carbohydrate . Research, 16, 199 (1971), while studyiny the s~ructure-function implication of the glycosaminoglycans, found that the amino function of certain amino acids can be ~.
covalently linked to the carboxyl group of a glycosaminoglycan. ThiS is, of cour~se, a conventional amidation; and while a similar reaction is employed in making some of the substances of the present invention~
Danishefsky and Siskovic did not make, or suggest the possibility of making, a prodrug.
Mill et al U.S. Patent 4~003,792 teaches that proteins may be bound to acid polysaccharides of plant origin, specifically alginic acid, pectic acid, celluronic acid, and carageenan~ Such polysaccharides are food carbohydrates, alien to the blood and tissues of anlmals, and are clearly distinct both chemically and physiologically from the chondroitins used in the present invention. While Mill et al indicate that their complexes may ~e used for preparing antisera and for slow release of antisera, they do not describe how slow release of antisera can be achieved. In contrast, the chondroitin complexes of the present invention are compatible with animal blood and tissue and are normally cleaved by body metabolism to release the active drug.
Yannas and Burke U.S. Patents 4,060,081 and 4,059~572 use the ionic properties of mucopolysaccharides (an older term essentially coextensive with th~ glycosaminoglycans) to flocculate or complex ionically with proteins. For example, an artificial skin formulation was prepared from chondroitin sulfate and collagen.
Heparin (a glycosaminoylycan) is very effective in slowing the clotting of blood, but is relatively short-acting when administered. A variety of derivatives have therefore been made to delay its absorption and prolong its pharmacological action.
Thus, Mardiguian and Fournier UOS~ Patent 3~835~112 esterifies the hydroxyl groups of heparin with long chain fatty acids to give insoluble complexes which slowly re-generate the ac-tive soluble heparin upon cleavage o~ the ester bond. Bernasconi et al (G~ Ital. Chemioter., 3, 79 (1956)) react heparin with tetracycline to produce a slowly soluble salt complex with a prolonged payout of heparin.
Laland Norwegian Patent 97,467 (1961) prepares a long-acting salt of adrenocorticotropic hormone (ACTH) and hyaluronic acid. The latter, a mammalian polyuronide, is a non-sulfated ; glycosaminoglycan, and perhaps for this reason -the complex shows no autocatalytic effect and no significant amount of fast hydrolysis.
The advantages of using the chondroitins in the preparation of prodrugs lie in the fact that such molecules are found throughout the body, are biocompa-tible, are not species-dependent, and are metabolically cleaved from the drug substance in pro-longed periods ranging from days to months.
In accordance with the present invention, a chondroitin is reacted in a known manner with a drug substance as hereinafter defined to produce a derivative which, upon injection into the body in the form of a solution or finely divided suspenslon, is metabolically decomposed to release the drug or a drug complex in therapeutically active form. The drug substance i.s released from the carrier by hydrolysis of the attachment bond in the case of covalently linked prodrugs, either by body fluids or by enzymes, or is released by enzymatic degrada-tion of the chondroitin matrix, or both; or by gradual ionization in the case of ionically linked prodrugs.
'~3~
,, . - 3a -According -to one aspect of the present invention there is provided a process for preparing a prodrug having chloramphen-icol, methotrexate, adriamycin, vinblastine, vincristine, vindesine, 6-mercaptopurine, 5-fluorouxacil, a penicillin antibiotic, a cephalosporin antibiotic, or a l-oxacephalosporin antibiotic as a pharmaceutically active constituent, which comprises esterifying, amidating, or ionically bonding said pharmaceutically active constituent or a reactive derivative thereof, with chondroitin-4-sulfate or chondroitin-6-sulfa-te, or a reactive derivative thereof, the prodrug having the property, when injected into animal tissue, of undergoing na-tural con-version in the physiological environment to provide a controlled release of said pharmaceutically ac-tive constituent or pharm-aceutically active complex thereof.
According to another aspect of the present invention there is provicled the prodrug product of the above process.
The repeating struc~ural unit of -the chondroitins is shown in the drawing. In the basic chondroitin struc-ture, both Q and R are hydroxyl. The 81~
chondroitins occur most commonly in one of ~wo forms, chondroitin-4-sulfate ~"C4S"), in which the hydroxyl at Q is sulfated, and chondroitin-6-sulfate ("C6S"), in which the hydroxyl at R is sulfated~ These substances are water-soluble; and depending upon the drug loading and the nature of the drug complex~ the prodrug product may be formulated as an aqueous solution or an aqueous colloidal suspension for injection into the patient.
As will be seen from the drawing, a variety of functional groups are availabl~ in the chondroitins for covalent bonding (particularly carboxyl, COOH/ and hydroxyl, 0~) and for ionic bonding tsulfate -OS03-, and carboxylate~ -COO~) with drugs. Covalent bonding can be by way of ester links, -COOY, or amide links, -CONHY, either directly to an appropriate functional group of the drug or by way of a bio~acceptable linking substance, e.g., an amino acid or ureaO Thus, drugs having the general formula X-Yn are suitable for use in the present invention, where X
; is or can be converted into a carboxyl, hydroxyl, sulfydryl, or amino function; n is an integer at least l; Y is the residue of the drug molecule -- i.e., its characteristic structllre exclusive of the reactive function X; and Y, when plural, may be the same or different groups. Illustrative ~rugs include pencillin G, pencillin V, ampicillin, carbenicillin, and the whole range of penicillin antibiotics, both natural and synthetic; cephalothin, cephaloridine, cephaloglycin, cephalexin, cephradine, cefa~olin, cefamandole, cefaclor, and the whole range of cephalosporin antibiotics, including the l-oxa, l-aza, and l-carbo analogues thereof; chloramphenicol; adriamycin (daunorubicin); methotrexate; vinblastine, vincristine, vindesine; 6-mercaptopurine; 5-fluorouracil; and the like.
Linking substances typically have the general formula Rl- Z_R2 where Rl~and R2 are or can be converted into carboxyl, hydroxyl, sulfhydryl, and amino functions and may be the : same ~r di~ferent, and where Z is an organic group~ the whole substance being bio-acceptable -- i,e., having no objectionable toxicity or pharmaceutical activity incompatible with the drug substance. Illustrative linking substances include urea, guanidine, glycineF
alanine, phenylalanine~ lysine, aspartic acid, glutamic acid, trimethylene glycol, 6-aminocaproic acid, thioglycQlic acid, an~ the like.
The reaction of the chondroitin with the drug substance to obtain the novel substances of the present invention is carried out in a known manner, depending upon the functional groups involved.
Where the chondroitin and the dru~ substance contain a hydroxyl group and a carboxyl group, respectively, the two can be reacted by use of a carbodiimide; or the carboxyl group can be converted to an acid chloride and reacted with the hydroxyl group; or the carboxyl group can be conver~ed to a mixed anhydride and reacted with the hydroxyl group. All of these procedures and the conditions required therein are old and well known in the ar~. The same procedures can be used when the chondroitin and the drug substance contain a carboxyl group and a hydroxyl groupl respectively. In all cases, the product is an ester. Sulfhydryl groups may be reacted in a manner analogous to hydroxyl groups.
When the chondroitin and the drug substance contain a hydroxyl and an amino group, respectively ~or vice versa3, the reaction can be caused to proceed through ormation of a carbamate bond via the activation of the hydroxyl to a chloroformate moiety with subsequent linking to the amine function. The procedure and proper reaction conditions are well known and conventional in the art. Similarly, a carbonate bond may be formed between two hydroxyl groups (on the chondroitin and on the drug~
When the chondroitin and the drug substance contain a carboxyl group and an amino group, respectively (or vice versa~, the reaction is one of conventional amide formation under known conditions employing known procedures~ eliminating a molecule of water between the two molecules~ Alternatively in such a case, the two substances may be reacted ionically in the presence of water to form a pro~uct in the nature of an ammonium salt. In the same way~ an acid sulfate or an acid sulfonate can be reacted with an amine to form a salt. The amine function of methotrexate~ for example~
can be converted to the quaternary ammonium form and subsequently complexed ionically with a chondroitin acidic function. Where one or both of the starting materials contains more than one functional group, it may be desirable to protect groups that are not desired to react, in order to avoid obtaining a mlxed product.
These are techniques which are well known in the artO
Linking molecules can convenien$1y be employed when the chondroitin and the drug substance do not contain mutually reactive functional ~roups -- for example~ when both contain carboxyl and neither contains primary aminoS NH~. In such a case, any substance can be employed as a linking agent which has two functional groupsy one capable of reacting with the chondroitin, the other with the drug. To link carboxyl groups, for examplet it is convenient to employ ure~, guanidine, or a bio-acceptable diamine such as ethylenediamine or trimethylenediamine~ reacted first with the chondroitin~
then with the drug substance, or vice versar Linking molecules can also be employed to overcome ~teric or other chemical problems in a given case.
The reaction products of the present invention are conveniently prepared for administration by dissolving in ~ater or in an isotonic salt solution~ or, in cases where the product is less soluble ~ by comminuting and suspending in water or an isotonic salt solution. In ~he la~ter case, the product can also be dissolved in an appropriate organic solvent such as 10 dimethylsulfoxide, dimethylformamide, or the like~
diluted with water to form a colloidal suspension, and vacuum stripped or dialyzed against water to remove the organic solvent. The solution or suspension may appropriately contain from about 5 to about 500 mg. of product per milliter as a suitable concentration for injection into the patient, and the volume injected is chosen to provide the desired drug dosage which will~ of course, vary with the drug substance.
We have found that the rates of hydrolysis of C4S and C6S drug complexes are similar for a given druy and loading, and exhiblt a significant initial amount of fast hydrolysis, even at low loading -- an effect not seen with compounds lacking the sulfate moiety. It is thus considered that the sulfates play a major role in the autocatalytic hydrolysis of C4S and C6S drug complexes.
The invention is illustrated by the fv].lowing ~pecific examples:
C4S~Chlora~ henicol Ester via C4S Acid Chloride To an anhydrous solution of the free acid o chondroitin-4-sulfate (C4S; 155.5 m5t prepared by ion exchange) and pyridine t0~2 ml) .in dimethylformamide R~
tDMF, 35 ml) is added a solution of thionyl chloride (46.5 mg3) in dimethylformamide (1 ml), and the mixture is stîrred at 60C for 20 minutes. To the resulting solution of C4S acid chloride is added a solution of chloramphenicol ~101.3 mg) in DMF ~2 ml) and stirrlng is continued for 21 hours at room temperature. The C4S-chloramphenicol ester prodrug product is then recovered by neutralizing the reac~.ion mixture with dilu~e sodium hydroxide, dialyzi~g extensively against water, and lyophilizing, yielding 172~8 mg of the C4S chloramphenicol ester prodrug.
15C6S-Chloramphenicol Ester via C6S Acid_Chloride In the same way~ the chonodroitin~6-sulfate ~C6Sj chloramphenicol ester prodrug is prepared by reaction of the free acid of C6S (40.5 mg), pyridine 20 (Ool ml), anhydrous dimethylsulfoxide (DMS0, 8.5 ml), thionyl chloride (3.7 mg in 0~8 ml DMF), and chloramphenicol (2008 mg in 1 ml DMF), yielding 22.4 mg of purified e~ter prodrug.
25EX~MPLE 3 C4S-Chloramphenicol Ester via C4S Mixed Anhydride To an anhydrous solution of the free acid of C4S (51.4 mg) in DMF (11 ml) is added pyridine (0.1 ml) and isobutyl chloroformate (ll.D mg in 0.75 ml D~), and the mixture is allowed to react at 0C for 20 minutes.
To the resulting solution of C4S mi~ed anhydride is added a solution of chloramphenicol (27.1 mg in 1 ml DMF) and stirring is continued for 15 minutes at 0C, then 12 hours at room temperatureO The product is isolated ~;
9 _ as in Example 1 by neu~raliæa~ion/dialysis/lyophllizatlon, yielding 49~1 mg of e~ter prodrug.
C6S-Chlor~phenicol Ester _ _ via C6S Mixed_Anhydride The ~5S-~hloramphenicol ester product is prepared according to the procedure of Example 3 by reacting C6S (40~5 mg) in DMS0 t8 ml) with isobutyl chloroforma~e (8.7 mg in 0.8 ml DMS03, pyridine (0.1 ml)~ and chloramphenicol (20~8 mg in 1 ml DM~).
Isolation as in .Example 1 yields 19.0 mg o C6S-chloramphenicol e~ter prodrug.
_XAMPLE 5 C4S Methotrexate Amide via Carbodiimide To a 501ution of C4S (10 mg) and methotrexate dimethyl ester trihydrochloride (12 mg) in a 1~1 D~F/H20 solution (3 ml) under nitrogen is added l-ethyl-3,3 dimethylaminopropyl carbodiimide ~EDC, 6 mg).
From the reaction product~ worked up as in Example 1, is recovered 14.1 mg of the C4S-methotrexate amide prodrugO
2S EXAMPL~ 6 C4S-Adr~ cin Amide _ via Carhodiimide To a 1:1 ~volume) mixture of DMF and water (1 ml) at pH 2 containing the fxee acid of C4S (5~1 mg) 30 is added adriamycin (5 mg) in 1:1 DMF/H~0 (1 ml3 with stirring. l-Ethyl-3~3-dimethylaminopropyl carbodiimide ~EDC, 3 mg) in water (0.5 ml) is then added at room temperature with .stirxing~ during which the pH of the mixture rises to 3.75. After 24 hours, the reaction product is neutralized with sodium bicarbonate, dialyzed extensively against water, and lyophilized. The C4S adriamycin amide prodrug is obtained as 6.5 mg of pure material.
C6$~Chlor~henicol Ester via Carbodiimide A solution of C6S (6809 mg) in water (5 ml) is added to a solution of chloramphenicol ~45~3 mg) in DMF (5 ml) and the pH is ad justed to 4 . 75 with dilu~e HCl. EDC (26.2 mg~ is added and the pH kept at 4 0 75 Eor one hour at room temperature. Workup as in Example 6 y;elds 33.7 mg of c6s~Ghloramphenicol ester prodrug~
C4S--Chloramph~nicol Est r via Carbodiimide A solution of the free acid of C4S (123~5 mg) 20 in anhydrous DMF (1.5 ml) is added to a DMF solution (0.2 ml) containing chloramphenicol (22.7 mg) and 4-pyrrolidinopyridine (4-PP, 18.5 mg) acylation catalystr follwed by dicyclohexyl-carbodiimide (DCC, 13. 5 mg~ in DMF (0. 2 ml), and held at -8C :Eor 36 hours.
The insoluble dîcyclohexylurea by-product is filtered of and discarded. To the filtrate is added 3 volumes of ether. The precipitate is filtered off, washed with ether and air dried, then redissolved in the minimum amoun~ (0.2 ml) of sodium phosphate buffer ~lM~ pH=7)~
The solid is precipitat~d again~ this time with 3 volumes of ethanol~ and washed with ether. The solid is again dissolved in phosphate buffer an~ reprecipitated as above. After a final ether wash and air drying~ a yield of 110.4 mg of pure C4S chloramphenicol ester 35 prodrug is obtainedO
EXAMPL~ 9 C6S-Chloram~henicol ~ster ia Acid Ca~alysis A portion of the free acid of C6S (50.2 mg) is placed in a vacuum oven over P2O5 at 110C overnight to remove water of hydration. The ~otal weight loss is lZ.5 mg. The dried material is dissolved in ~nhydrous dimethyl sulfoxide (DMSO, 3 ml) together with chloramphenicol (94,0 mg~ and trifluoracetic acid (0.01 ml) to serve as an acid catalyst. ~he mixture is stirred at 80C for 20 hours, then worked up as in Example 1. A yield of 16D 4 mg of C6S-chloramphenicol ester prodrug is ohtained.
A carboxyl function of a chondroitin can be esterified to an intermediate moiety possessing an alcohol function~ for example ethanol, and the chondroi.tîn-ethyl ester can then be transesterified with a hydroxyl group of a drug or an intermediate linking group under acidic conditions. These methods are illustrated in the two following examples.
EXAMPLE 10 .
C4S-Chloramph~nicol Ester by Transe~t~ _ The ethyl ester of C4S is made by the ~ollowing method~ C4S (1~09~ g] is suspended in anhydrous DMF ~50 ml) at 60 Cr and ethyl iodide ~2~5 ml, recently distilled) is added. Stirring is continued for 4 days at 60C, after which the suspension is filtered, the residue washed twice with ether, redissolved in phosphate bufer (lM~ pH=7~ r and, precipitated from 3 volumes of ethanol. The .resulting pellet is washed with ether, redissolved in water, and . reprecipitated from ethanol to yield 0.958 g of the ethyl ester of C4So Transesterification of the ethyl ester of C4S
by a hydroxyl function of chloramphenicol is accomplished by adding the ethyl ester of C4S as produced above (57.0 mg) to chloramphenicol (20.2 mg) and trifluoracetic acid (0~001 ml) in anhydrous DMF
(5 ml). After 4 days at 60Cv ~he product is filtPred and worked up in Example 1, yielding 43~2 mg of the ester prodrug o chloramphenicol and C4S.
EX~MPLE 11 ~4S-Chlor~phenicol Ester by Transesterification An alternative route of making C4S-ethyl ester is to dissolve the free acid of C4S (60~1 mg) in anhydrous DMF ~5 ml) and then add DCC (2509 mg) in DME' (0.3 ml~ followed after 10 minutes by sodium ethoxide (29.3 mg). Stirring at room temperature for 18 hours produces a viscous solution. The product is i501 ated by removal o DMF (40C in vacuo) and trituration in ether;
yield, 65~0 mg of the ethyl ester of C4S.
Transesterification of the C4S ethyl ester with a hydroxyl function of chloramphenicol is carried out by dissolving the C4S ethyl ester (58,1 mg), chloramphenicol (20.2 mg), and trifluoroacetic acid (0.001 ml~ in anhydrous DMF (5 ml)~ Stir.ring at 60C
for 4 days and working up the reaction product mixture as in Example 1 yields 34.~ mg o C4S-chloramphenicol ester prodrug~
C4S-Me~hotrexate Ester via Transesterification The hydroxyl groups of a chondroitin can be used in a transesterification reactîon with an ester function of a drug to yield the acylated chondroltin, ;
i.~., ~he chondroitin es~er prodrug. For example~ a hydroxyl function of C4S can be reacted with the dimethyl ester trihydrochloride of methokrexate to yield an ester-linked C4S-methotrexate prodrug according to the following procedure.
To a solutlon of the free acid of C4S
(41.6 mg) in anhydrous DM~ ~10 ml) is added methotrexate dimethyl ester trihydrochloride (2707 mg) and trifluoracetic acid (0.001 ml) as acid catalyst.
Stirring at 60C for 7 days under anhydrous conditions and product isolation as in Example 1 yields 35.4 mg of the C4S-methotrexate ester prodrug.
The hydroxyl functions of a chondroitin can be caused to react with an activated carboxyl group of a drug or an intermediate linking substance to produce an ester bond. Activation of the molecule to be attached to the chondroitin is achieved by well-known standard methods such as by conversion to the acid chloride or mixed anhydride, by use of carbodiimide, or by use of acid catalyzed transesterification methods. These procedures will be elucidated in th~ following two examples.
C4S-Penicillin V Ester via Mixed Anhydride The carboxyl group of phenoxymethyl penicillin (penicillin V) is ester-linked to the hydroxyl gr3up of C4S by `the following mixed annhydride procedure.
Penicillin V free acid ~3.04 9~ is dissolved in a cold (5C) mixture of DMF (50 ~1) and pyridine (0.80 g), and isobutyl chloroformate (1.19 g~ is added with stirring.
The mixture is held at ~10c with stirring for 30 minutesO The mixed anhydride reaction product is not isola~ed, but is added ~ se to a solution of the ~ree acid o~ C4S ~1.48 g) in DMF at room ~emperature. After stirring for 6 hours, the C4S~penicillin V est2r prodrug is precipitated from solution with an excess of ether J
iltered, neutralized with dilute sodium hydroxide~ and lyophilized. The yield is 1~14 g of purified product~
While the ahove scheme employs a mixed anhydride, a symmetrical anhydride can also be used;
i.e., by converting penicillin V into its symmetrical anhydricle in a known manner.
C4S-Penicillin V Ester via Carbodiimide The reaction of the carboxyl group of penicillin V free acid with a hydroxyl group of C4S can be carried out directly by use of a carbodiimid~
according to the following procedure. Penicillin V free acid (1.41 g) and EDC (0.64 g) are dissolved in anhydrous DMF (50 ml~ and added to a solution of C4S
20 free acid (1.79 9) and pyridine ~1.5 ml) in DMF
(180 ml), after which the mixtue is stirred and held at room temperature for six hours~ The product is isolated as described in Example 13, yielding 1.41 g nf the C4S-penicillin V ester prodrug~
The ionic (acidic) nature of the chondro.it.ins can be used to form ionic complexes (salts) with drugs or with drugs attached to an intermediate linkiny molecule that is basic or can be made basic. The following three examples illustrate this concept.
: EXAMPLE 15 C4S-Adriam~cin Ionic Complex An aqueous solution (1 ml) of the sodium salt of C4S (5.1 mg) is dropped into an aqueous solution (1 ml) of the hydrochloric acid ~alt of adriamycin (6 mg). The mixture is stirred at room temperature for 24 hours and subseauently neutralized with a solution of sodium bicarbonate, dialyzed extens;vely ag~inst water~
and lyophilizedO Obtained is 8.8 mg of the ; C4S-adriamycin ionic complexO
C6S-Alanine-Chlorampherlicol ~
Drugs which do not include a basic moiety (e,g., a quaternary ammonium group) may be derivatized in such a way as to introduce a basic function to complex with the acidic function of a chondroitin to produce an ionic complex. Illustrative of this is the derivati~ation of the hydroxyl groups of chloramphenicol with the carboxyl group of an intermediate linking group, alanine, to orm an e5terO The ammonium ~unction of the alanine-chloramphenicol ester is then complexed with a chondroitin to make a polymeric prodrug salt.
The alanine-chloramphenicol ester is synthesized by dissolving chloramphenicol (12.906 g);
: N-carbobenzoxy-L-alanine ~lOo 003 9) ~ and 4-pyrrolidinopyridine ~0.597 g) in anhydrous tetrahydro~uran (THF, 30 ml3. A solution of dicyclohexylcarbodiimide (DCC 8.660 g) in T~F ~15 ml) is added dropwi5e to the above with stirring at room temperature. After 17 hours, the insoluble dicyclohexylurea by-product is filtered o~E and th~
30 ~olvent stripped o$ ln vacuo at 40C to yield a yellow oil. The oil is taken up in dichloromethane ~300 ml~ and extracted successively with three 2Q0 ml portions of each of the following in the order namedo saline~ 5%acetic acid in saline, saturated sodium bicarbonate, and saline. The organic layer is dried over anyhdrous maynesium sulfate and concentrated to about 20 ml. Addition of 3~% ~Br in acetic acid (40 ml~
to this solution under anhydrous conditions at room temperature over a period of 2 hours removes the protective group from the amino function of the alanine~
A large excess ~450 ml) of anhydrous ethyl ether is added to the solution, causing the hydrobromide salt of the alanine-chloramphenicol ester to precipitate outO
Decanting and trituration in ether followed by recrystallization from anhydrous DMF/ether yields 18~693 g of the salt as a hygroscopic wbite powder~
The hydrobromide salt of the al~nine-chloramphenicol ester produced above ~44.8 mg3 in water (0.5 ml) is added dropwise to a stirred aqueous ~1 ml) solution of C65 (29.9 mg) at room temperatureO After 4 hours, the mixture is worked up as in Example 1 to yield 38~7 mg of the C6S-alanine~chloramphenicol prodrug.
C4S-Alanine-ChloramRhenicol onic Complex Reaction of C4S (29.8 mg) and alanine-chloramphenicol hydrobromide (44.5 mg) according to the procedure oE Example 16 yields 35.2 mg of the C4S-alanine-chloramphenicol prodrug.
C~S-Urea-Penicillin V
The carboxyl group of penicillin V is amide-linked to a glycosaminoglycan through the amine function of urea as an intermediate linking molecule according to the following procedure. C4S (8210 5 mg~
and urea (757.8 mg) are dissolved in water (15 ml) at p~ 4.75. EDC ~434.9 mg~ is added and the p~ kept at 4.75 for 5 hours at ro~m temperature~ The C4S urea amide-linked intermediate is isolated by dialysis and lyophilization. A portion of the C4S-urea (251.5 mg) and penicillin V potassium sal~ (410~5 mg~ are dissolved in water (15 ml) and the p~ is adjusted to 6Ø EDC
~20900 mg) is added and the same pH maintained for 5 hours, after which the mixture is worked up as in Example 1, yielding the C4S-urea-pencillin V prodrug.
EXAMPLÆ 19 C6S-6-Aminocaproic Acid~Chloramphenicol Long-chain linking molecules containing appropriate functional groups on both ends of the molecule are especially useful in linking a drug with a chondroitin when the poin~ of a~achment on the drug is sterically hinaered. Drug and linkex may be attached in high yield, followed by reaction with the chondroitin.
As an example of such a linker, 6-aminocaproic ~cid is attached to chloramphenicol in the same manner as alanine (Example 161. N-carbobenzoxy-6-aminocaproic acid (550.1 mg), chloramphenicol (54B.7 mg), and 4~pyrrolidinopyridine (25.4 mg) in dry THF (10 ml) are reacted with-DCC- (394.4 mg) in dry THF (2 ml); .and after 16 hours at rvom temperature and purification as in Example 16, the oil obtained is reacted with 30%
HBr/acetic acid (5 ml1 at room temperature for 1 hour.
Further purification as before yields 38~.0 mq of the ester-linked chloramphenicol-6-aminocaproic acid hydrobromide.
The hydrobromide product thus obtained (292.'~ mg) and the sodium salt of C6S (15~.9 mg) are ~ 30 dissolved in 2~1 DMF/water (2.5 ml) and the pH is ; adjusted to 4.75~ A solution of EDC (125~2 mg) in 2:1 ~ DMF/water ~005 ml) is added slowly and the p~ kept at ; 4.75 for three hours with stirring at room te~peratureO
Purification is carried out as in Example 1 to ~ield ~- ~8 ~
189.4 mg of the chloramphenicol-6-aminocaproic acid-C6S
prodrug.
6S-Alanine 14C~Chloram~henicol Chloramphenicoll radio-labelled with 14C at both of its dichloroacetyl functions~ is amide-linked through alanine to C6S by the following procedure~
generally paralleling Example 16.
The sodium salt of C6S l3-024 g~ and the radio labelled 14C-chloramphenicol~alanine hydrohromide (prepared as in Example 16 7 5.173 9) are dissolved in
2:1 DMF/water ~55 ml), and the p~ is brought to 4u75.
To this solution is added a solution o~ EDC (2.075 g) in 2:1 DMF/water (10 ml~ slowly over a period of 1.5 hours, keeping the pH at 4.75. After an additional 2 hours' stirring at room temperature, the solution is neutralized with dilute sodium hydroxide and then dialyzed extensively against water and lyophilized~
Purified C65-alanine-14Cchloramphenicol prodrug is obtained in a 3.890 g yield.
Tests are carried out on the C6S-alanine-14Cchloramphenicol prodrug by injection as a solution in sterile saline ~145 mg/ml) into the flanks o~ 8 white female rats weighing from 0.3 to 0O4 kg each.
The prodrug contains 18u6% by weight of chloramphenicol, and the injection volumes (averaging about 2.5 ml) are chosen to prvduce a dosage equivalent to ~00 mg of chloramphenicol per kg of rat body weight and a radioactivity dosag~ of 0.50 ~Ci per kg. Urine and feces are col~ected and counted for radioactivity~ The results are as follows:
Days After In~ection Cumulative % of Dru~ eleased 0~8 3 1.3 6 n~L~U~ D9~JA~ Cumulative % o~ Drug Released 108 81.4 2.2 87~1 2.~ 89 D
To this solution is added a solution o~ EDC (2.075 g) in 2:1 DMF/water (10 ml~ slowly over a period of 1.5 hours, keeping the pH at 4.75. After an additional 2 hours' stirring at room temperature, the solution is neutralized with dilute sodium hydroxide and then dialyzed extensively against water and lyophilized~
Purified C65-alanine-14Cchloramphenicol prodrug is obtained in a 3.890 g yield.
Tests are carried out on the C6S-alanine-14Cchloramphenicol prodrug by injection as a solution in sterile saline ~145 mg/ml) into the flanks o~ 8 white female rats weighing from 0.3 to 0O4 kg each.
The prodrug contains 18u6% by weight of chloramphenicol, and the injection volumes (averaging about 2.5 ml) are chosen to prvduce a dosage equivalent to ~00 mg of chloramphenicol per kg of rat body weight and a radioactivity dosag~ of 0.50 ~Ci per kg. Urine and feces are col~ected and counted for radioactivity~ The results are as follows:
Days After In~ection Cumulative % of Dru~ eleased 0~8 3 1.3 6 n~L~U~ D9~JA~ Cumulative % o~ Drug Released 108 81.4 2.2 87~1 2.~ 89 D
3 r 3 90 ~ 5 3~g 91~9 S~O 93~
~i~O 95~0 7~ 9~;~0 In order to test the efficacy of the prodrug, blood samples (2 ml) are taken from two of the rats and assayed for antibiotically active chloramphenicol against Sarcina lutea (ATCC 9341) by the method described in 21 Code of Federal Regulationsr Subpart D, paragraphs 43~.100 to 436~105r inclusive, revised April 1, 1976, When measuxed 23 hours after injection, the prodrug shows a plasma chloramphenicol concentration of 17.5 ~g/ml by microbiological assay and 390 ~ g/ml by radioactive counting. In contrast, rats injected with ree 14C-Chloramphenîcol show a plasma concentration 5 5 hours ater injection o 37.5 ~g/ml by microbiological assay and 325 ~/ml by radioa~tive counting; and the drug is completely cleared from the plasma at the end of 12 hours.
~he prodrug itself, when tested by microbiological assay, has an activity equivalent to only 1.2 weight~ of chloramphenicol.
-C4S Alanine-14C=Chloramphenicol The procedure o~ Example 20 is repeated wi$h the sodium salt of C4S (3~016 g) and radioactiv~
chloramphenicol-alanine hydrobromide (5~133 g~ in 2:1 DMF/water (55 ml), and a solution of EDC [2.074 9) in 2~1 DMF/water (10 ml)~ yieldin~ 3.894 g of purified B~
C4S alanine-~4C-chloramphenicol prodrug containing 19.4%
by weight of chloramphenicol. The prodrug is tested by injection into seven white female rats in the equivalent dosages and according to the procedure of Example 20.
The results are as follows:
Day~ ectionCumulative % of Dru~ Released ~.7 35.6 1.3 58.7 1.7 76.7 2.2 82.9 ~.8 86~6 3.3 8~.2 3~9 ~9.7 5.0 91.6 6.0 93.0 ; 7.0 94.2 Blood samples drawn from two of the rats at the end o 22.5 hours show a plasma concentration of 22.5 ~Lg/ml by microbiological assay and a concentration o 485 ~g/ml by radioactive counting. The prodrug itself, when subjected to microbiological assay, shows an activity equivalent to only 1.5 weight-% of chloramphenicol..
~ he xate of release of the drug from the chond.roitin or from the linking substance, îf used~ is dependent on the type of bond(s~ chosen for the linkage(s). Thus, although enzymatic mechanisms must be considered and may be controlliny in some instances, the release rates of the chondroitin prodrug formulations are ordinarily expected to follow their order of hydrolytic stabilityO Therefore~ ester hydrolyzes faster than amide, etc. The following two examples illustrate this concept.
:' EXAMPLÆ 22 Dru~_Release Ra~e From C6S-Alanine-Chloramphenicol In vitro hydrolysis of a prodrug sample in a "physiological" solution can be an ef$ective guide in pxedicting ~he release behavior of the prodrug in vivo.
A C5S alanine-chloramphenicol prodrug synthesized according to the procedure outlined in Example 20 and assaying 5.0% chloramphenicol by weight îs dissolved in 4 ml of a "physiological" buffer solution containing 0.15M NaCl and 0.05M Tris buffer, pH 7.4. The resulting solution is placed in a small diameter dialysis tube lt retain th~ prodrug yet allow free drug to readily pass) and dialyzed at 37C against the same physiological buffer solution ~81 ml~.
Ultraviolet analysis of the dialysate at 274 nm gives the following results:
D~ % of Dose Released 0.1 6.6 22.5 2.2 41.0 3.8 50.0 g.l 70.2 15.1
~i~O 95~0 7~ 9~;~0 In order to test the efficacy of the prodrug, blood samples (2 ml) are taken from two of the rats and assayed for antibiotically active chloramphenicol against Sarcina lutea (ATCC 9341) by the method described in 21 Code of Federal Regulationsr Subpart D, paragraphs 43~.100 to 436~105r inclusive, revised April 1, 1976, When measuxed 23 hours after injection, the prodrug shows a plasma chloramphenicol concentration of 17.5 ~g/ml by microbiological assay and 390 ~ g/ml by radioactive counting. In contrast, rats injected with ree 14C-Chloramphenîcol show a plasma concentration 5 5 hours ater injection o 37.5 ~g/ml by microbiological assay and 325 ~/ml by radioa~tive counting; and the drug is completely cleared from the plasma at the end of 12 hours.
~he prodrug itself, when tested by microbiological assay, has an activity equivalent to only 1.2 weight~ of chloramphenicol.
-C4S Alanine-14C=Chloramphenicol The procedure o~ Example 20 is repeated wi$h the sodium salt of C4S (3~016 g) and radioactiv~
chloramphenicol-alanine hydrobromide (5~133 g~ in 2:1 DMF/water (55 ml), and a solution of EDC [2.074 9) in 2~1 DMF/water (10 ml)~ yieldin~ 3.894 g of purified B~
C4S alanine-~4C-chloramphenicol prodrug containing 19.4%
by weight of chloramphenicol. The prodrug is tested by injection into seven white female rats in the equivalent dosages and according to the procedure of Example 20.
The results are as follows:
Day~ ectionCumulative % of Dru~ Released ~.7 35.6 1.3 58.7 1.7 76.7 2.2 82.9 ~.8 86~6 3.3 8~.2 3~9 ~9.7 5.0 91.6 6.0 93.0 ; 7.0 94.2 Blood samples drawn from two of the rats at the end o 22.5 hours show a plasma concentration of 22.5 ~Lg/ml by microbiological assay and a concentration o 485 ~g/ml by radioactive counting. The prodrug itself, when subjected to microbiological assay, shows an activity equivalent to only 1.5 weight-% of chloramphenicol..
~ he xate of release of the drug from the chond.roitin or from the linking substance, îf used~ is dependent on the type of bond(s~ chosen for the linkage(s). Thus, although enzymatic mechanisms must be considered and may be controlliny in some instances, the release rates of the chondroitin prodrug formulations are ordinarily expected to follow their order of hydrolytic stabilityO Therefore~ ester hydrolyzes faster than amide, etc. The following two examples illustrate this concept.
:' EXAMPLÆ 22 Dru~_Release Ra~e From C6S-Alanine-Chloramphenicol In vitro hydrolysis of a prodrug sample in a "physiological" solution can be an ef$ective guide in pxedicting ~he release behavior of the prodrug in vivo.
A C5S alanine-chloramphenicol prodrug synthesized according to the procedure outlined in Example 20 and assaying 5.0% chloramphenicol by weight îs dissolved in 4 ml of a "physiological" buffer solution containing 0.15M NaCl and 0.05M Tris buffer, pH 7.4. The resulting solution is placed in a small diameter dialysis tube lt retain th~ prodrug yet allow free drug to readily pass) and dialyzed at 37C against the same physiological buffer solution ~81 ml~.
Ultraviolet analysis of the dialysate at 274 nm gives the following results:
D~ % of Dose Released 0.1 6.6 22.5 2.2 41.0 3.8 50.0 g.l 70.2 15.1
Claims (42)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for preparing a prodrug having choramphenicol, methotrexate, adriamycin, vinblastine, vincristine, vindesine, 6-mercaptopurine, 5-fluorouracil, a penicillin antibiotic, a cephalosporin antibiotic or a 1-oxacephalosporin antibiotic as a pharmaceutically active constituent, which comprises esterify-ing, amidating, or ionically bonding said pharmaceutically active constituent or a reactive derivate thereof, with chondroitin-4-sulfate or chondroitin-6-sulfate, or a reactive derivative thereof the prodrug having the property, when injected into animal tissue, of undergoing natural conversion in the physiological environment to provide a controlled release of said pharmaceutically active constituent or pharmaceutically active complex thereof.
2. A process according to claim 1 comprising esterify-ing chloramphenicol with chondroitin-4-sulfate or chondroitin-6-sulfate.
3. A process according to claim 1 comprising amidating methotrexate.
4 A process according to claim 1 comprising ionically bonding methotrexate.
5. A process according to claim 1 comprising amidating adriamycin.
6. A process according to claim 1 comprising ionically bonding adriamycin.
7. A process according to claim 1 comprising esterify-ing penicillin V.
8. A process according to claim 1 wherein said pharmaceutically active constituent is bonded to said chondroitin-4-sulfate or said chondroitin-6-sulfate by esterification, amidation, or ionic bonding through a linking substance.
9. A process according to claim 8 comprising esterify-ing chloramphenicol with alanine and ionically bonding the resulting ester with chondroitin-4-sulfate or chondroitin-6-sulfate.
10. A process according to claim 8 comprising esterify-ing chloramphenicol with alanine and amidating the resulting ester.
11. A process according to claim 8 comprising esterify-ing chloramphenicol with 6-aminocaproic acid and amidatins the resulting ester.
12. A process according to claim 8 comprising amidating chondroitin-4-sulfate or chondroitin 6-sulfate with urea and amidating the resulting amide with pencillin V.
13. A process according to claim 1 comprising esterify-ing 6-mercaptopurine with chondroitin-4-sulfate or chondroitin-6-sulfate.
14. A process according to claim 8 wherein said pharmaceutically active constituent is 5-fluorouracil.
15. A prodrug as defined in claim 1 whenever prepared by a process according to claim 1 or by an obvious chemical equivalent thereof.
16. A chloramphenicol prodrug whenever prepared by a process according to claim 2 or by an obvious chemical equivalent thereof.
17. A methotrexate prodrug whenever prepared by a process according to claim 3 or 4 or by an obvious chemical equivalent thereof.
18. A adriamycin prodrug whenever prepared by a process according to claim 5 or 6 or by an obvious chemical equivalent thereof.
19. A penicillin V prodrug whenever prepared by a process according to claim 7 or 12 or by an obvious chemical equivalent thereof.
20. A chloramphenicol prodrug whenever prepared by a process according to claim 9, 10 or 11 or by an obvious chemical equivalent thereof.
21. A 6-mercaptopurine prodrug whenever prepared by a process according to claim 13 or by an obvious chemical equivalent thereof.
22. A 5-fluorouracil prodrug whenever prepared by a process according to claim 14 or by an obvious chemical equivalent thereof.
23. A chondroitin-4-sulfate or chondroitin-6-sulfate con-taining prodrug whenever prepared by a process according to claim 8 or by an obvious chemical equivalent thereof.
24. A process for preparing C4S-chloramphenicol ester which comprises reacting the free acid of chondroitin-4-sulfate with thionyl chloride followed by reacting the C4S-acid chloride so formed with chloramphenicol.
25. A process for preparing C6S-chloramphenicol ester which comprises reacting the free acid of chondroitin-6-sulfate with thionyl chloride followed by reacting the C6S acid chloride so formed with chloramphenicol.
26. A process for preparing C4S-chloramphenicol ester which comprises reacting the free acid of chondroitin-4-sulfate with isobutyl chloroformate followed by reacting the C4S mixed anhydride so formed with chloramphenicol.
27. A process for preparing C6S-chloramphenicol ester which comprises reacting the free acid of chondroitin-6-sulfate with isobutyl chloroformate followed by reacting the C6S mixed anhydride so formed with chloramphenicol.
28. A process for preparing C6S-chloramphenicol ester which comprises reacting chondroitin-6-sulfate with chloramphenicol and 1-ethyl-3,3-dimethylaminopropyl carbodiimide.
29. A process for preparing C4S-chloramphenicol ester which comprises reacting the free acid of chondroitin-4-sulfate with chloramphenicol and dicyclohexyl-carbodiimide.
30. A process for preparing C6S-chloramphenicol ester which comprises reacting chondroitin-6-sulfate with chloramphenicol in admixture with trifluoracetic acid as catalyst.
31. A process for preparing C4S-chloramphenicol ester which comprises reacting chondroitin-4-sulfate with ethyl iodide followed by reacting the ethyl ester of C4S so formed with chloramphenicol in admixture with trifluoracetic acid as catalyst.
32. A process for preparing C4S-chloramphenicol ester which comprises reacting the free acid of chondroitin-4-sulfate with dicyclohexyl-carbodiimide followed by reaction with sodium ethoxide and then reacting the ethyl ester of C4S so formed with chlor-amphenicol in admixture with trifluoracetic acid as catalyst.
33. A process for preparing C6S-alanine-chloramphenicol which comprises reacting chloramphenicol and N-carbobenzoxy-L-alanine with dicyclohexylcarbodiimide followed by removal of the carbo-benzoxy amino protecting group with hydrogen bromide and reacting the hydrobromide salt of the alanine-chloramphenicol ester so formed with chondroitin-6-sulfate.
34. A process for preparing C4S-alanine chloramphenicol which comprises reacting chloramphenicol and N-carbobenzoxy-L-alanine with dicyclohexylcarbodiimide followed by removal of the carbo-benzoxy amino-protecting group with hydrogen bromide and reacting the hydrobromide salt of the alanine-chloramphenicol ester so formed with chondroitin-4-sulfate.
35. A process for preparing C6S-6-aminocaproic acid-chlor-amphenicol which comprises reacting N-carbobenzoxy-6-aminocaproic acid and chloramphenicol with dicyclohexylcarbodiimide followed by removal of the carbobenzoxy amino-protecting group with hydrogen bromide and reacting the ester-linked chloramphenicol-6-amino caproic acid hydrobromide so formed with a sodium salt of chondroitin-6-sulfate.
36. C4S-Chloramphenicol ester whenever prepared by a process according to claim 24, 26 or 29 or by an obvious chemical equivalent thereof.
37. C4S-Chloramphenicol ester whenever prepared by a process according to claim 31 or 32 or by an obvious chemical equivalent thereof.
38. C6S-Chloramphenicol ester whenever prepared by a process according to claim 25, 27 or 28 or by an obvious chemical equivalent thereof.
39. C6S-Chloramphenicol ester whenever prepared by a process according to claim 30 or by an obvious chemical equivalent thereof.
40. C6S-Alanine-Chloramphenicol whenever prepared by a process according to claim 33 or by an obvious chemical equivalent thereof.
41. C4S-Alanine-Chloramphenicol whenever prepared by a process according to claim 34 or by an obvious chemical equivalent thereof.
42. C6S-6-Aminocaproic Acid-Chloramphenicol whenever prepared by a process according to claim 35 or by an obvious chemical equivalent thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27972481A | 1981-07-02 | 1981-07-02 | |
| US279,724 | 1981-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1188988A true CA1188988A (en) | 1985-06-18 |
Family
ID=23070168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000406418A Expired CA1188988A (en) | 1981-07-02 | 1982-06-30 | Chondroitin drug complexes |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4489065A (en) |
| EP (1) | EP0083367A1 (en) |
| AU (1) | AU8762982A (en) |
| CA (1) | CA1188988A (en) |
| WO (1) | WO1983000150A1 (en) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4585754A (en) * | 1984-01-09 | 1986-04-29 | Valcor Scientific, Ltd. | Stabilization of proteins and peptides by chemical binding with chondroitin |
| IT1186772B (en) * | 1985-10-10 | 1987-12-16 | Crinos Industria Farmaco | COMPOUND WITH PILOSTIMULATING ACTIVITY |
| EP0224987B1 (en) * | 1985-11-29 | 1992-04-15 | Biomatrix, Inc. | Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same |
| DE3601136A1 (en) * | 1986-01-16 | 1987-07-23 | Max Planck Gesellschaft | INHIBITORS OF REVERSE TRANSCRIPTASE FOR PROPHYLAXIS AND THERAPY OF RETROVIRUS INFECTIONS IN MAMMALS |
| DE3680524D1 (en) * | 1986-04-22 | 1991-08-29 | Valcor Scient Ltd | PROCESS FOR STABILIZING PROTEINS. |
| EP0254845A3 (en) * | 1986-06-10 | 1989-04-19 | Lescarden Inc. | Immune stimulation with chondroitin sulfate |
| US5707604A (en) * | 1986-11-18 | 1998-01-13 | Access Pharmaceuticals, Inc. | Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles |
| GB8713662D0 (en) * | 1987-06-11 | 1987-07-15 | Skandigen Ab | Hyaluronic acid derivatives |
| DE3881615T2 (en) * | 1987-09-08 | 1993-09-23 | Takeda Chemical Industries Ltd | WATER-INSOLUBLE CYTOKINS. |
| US4952394A (en) * | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
| US5028697A (en) * | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
| US5141928B1 (en) * | 1989-12-20 | 1995-11-14 | Brujo Inc | Ophthalmic medication |
| US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
| US5382582A (en) * | 1993-03-26 | 1995-01-17 | Chan; Carcy L. | Methotrexate analogs and methods of using same |
| US6051576A (en) * | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
| EP0794796A1 (en) * | 1994-12-22 | 1997-09-17 | Access Pharmaceuticals, Inc. | Complexes of dermatan sulfate and drugs, giving improved pharmacokinetics |
| US5698556A (en) * | 1995-06-07 | 1997-12-16 | Chan; Carcy L. | Methotrexate analogs and methods of using same |
| US6106866A (en) * | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
| US6063370A (en) * | 1996-04-05 | 2000-05-16 | The Board Of Trustees Of The University Of Illinois | Macromolecular complexes for drug delivery |
| US5935599A (en) * | 1996-10-28 | 1999-08-10 | The Board Of Trustees Of The University Of Illinois | Polymer-associated liposomes for drug delivery and method of manufacturing the same |
| US20070185032A1 (en) * | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US6346519B1 (en) | 1998-09-09 | 2002-02-12 | Advanced Medical Instruments | Method and composition for treating arthritis |
| DE69926770T2 (en) * | 1998-10-05 | 2006-06-29 | Kabushiki Kaisha Yakult Honsha | ANTIBACTERIAL AGENTS AND METHOD OF MANUFACTURE THEREOF |
| AU2007200916B2 (en) * | 1998-10-05 | 2009-09-17 | Kabushiki Kaisha Yakult Honsha | Antibacterial agents and process for producing the same |
| WO2000021572A2 (en) * | 1998-10-09 | 2000-04-20 | The University Of Michigan | Hydrogels and water soluble polymeric carriers for drug delivery |
| IT1318403B1 (en) * | 2000-03-17 | 2003-08-25 | Cooperativa Ct Ricerche Poly T | POLYSACCHARID ESTERS OF N-DERIVATIVES OF GLUTAMIC ACID. |
| US6417237B1 (en) * | 2000-06-08 | 2002-07-09 | The Board Of Trustees Of The University Of Illinois | Macromolecular drug complexes and compositions containing the same |
| US8314060B2 (en) * | 2000-09-05 | 2012-11-20 | Biosight Ltd. | Peptide conjugated anti-cancer prodrugs |
| IL154696A (en) * | 2000-09-05 | 2008-11-03 | Biosight Ltd | Peptide conjugated anti-cancer prodrugs |
| DK1320387T3 (en) * | 2000-09-13 | 2012-07-16 | Glaxosmithkline Llc | Pharmaceutical compositions for sustained release of peptides |
| AU2002215180A1 (en) * | 2000-10-12 | 2002-04-22 | Orchid Chemicals And Pharmaceuticals Limited | Beta-lactam antibiotic-polysaccharide complex |
| WO2002087586A1 (en) * | 2001-04-26 | 2002-11-07 | Control Delivery Systems, Inc. | Sustained release drug delivery system containing codrugs |
| US20040022853A1 (en) * | 2001-04-26 | 2004-02-05 | Control Delivery Systems, Inc. | Polymer-based, sustained release drug delivery system |
| IN2014DN10834A (en) * | 2001-09-17 | 2015-09-04 | Psivida Inc | |
| US20040029774A1 (en) * | 2002-08-06 | 2004-02-12 | Aly Gamay | Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies |
| US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
| CA2504287A1 (en) * | 2002-11-26 | 2004-06-10 | Nobex Corporation | Natriuretic compounds, conjugates, and uses thereof |
| JP2006520392A (en) * | 2003-03-13 | 2006-09-07 | コントロールド・ケミカルズ・インコーポレーテッド | Compounds and methods for reducing drug abuse potential and extending duration of action |
| WO2005085294A1 (en) | 2004-03-05 | 2005-09-15 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid/methotrexate compound |
| US7807675B2 (en) * | 2004-04-02 | 2010-10-05 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
| US20070294127A1 (en) * | 2004-08-05 | 2007-12-20 | Viewscore Ltd | System and method for ranking and recommending products or services by parsing natural-language text and converting it into numerical scores |
| WO2006031614A2 (en) * | 2004-09-10 | 2006-03-23 | Tosk, Inc. | Reduced toxicity methotrexate formulations and methods for using the same |
| US20060105941A1 (en) * | 2004-11-12 | 2006-05-18 | Allergan, Inc. | Mixed antibiotic codrugs |
| WO2006076471A2 (en) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
| WO2007062403A2 (en) | 2005-11-28 | 2007-05-31 | Vernon D Rowe | Compositions useful for reducing nephrotoxicity and methods of use thereof |
| US8862591B2 (en) | 2006-08-22 | 2014-10-14 | Twitter, Inc. | System and method for evaluating sentiment |
| CA2729613C (en) | 2008-03-03 | 2017-02-07 | Tosk, Incorporated | Methotrexate adjuvants to reduce toxicity and methods for using the same |
| ITMI20121316A1 (en) * | 2012-07-27 | 2014-01-28 | Altergon Sa | CONDROTIC COMPLEXES FOR TRANSCUTANEOUS ABSORPTION |
| US10675354B2 (en) | 2013-07-10 | 2020-06-09 | Seikagaku Corporation | Glycosaminoglycan derivative and method for producing same |
| JP6453214B2 (en) * | 2013-07-10 | 2019-01-16 | 生化学工業株式会社 | Glycosaminoglycan derivative and method for producing the same |
| WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| CN105859912B (en) * | 2016-05-05 | 2018-10-19 | 扬州大学 | Chondroitin sulfate derivatives of a kind of nanometer of methotrexate (MTX) and preparation method thereof, purposes |
| JPWO2018199174A1 (en) * | 2017-04-25 | 2020-02-27 | 生化学工業株式会社 | Tertiary amine compound or imine compound-polymer conjugate and method for producing the same |
| US20210015933A1 (en) * | 2018-03-30 | 2021-01-21 | Seikagaku Corporation | Bioactive carboxylic acid type compound-polymer conjugate, and method for manufacturing the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1305807A (en) * | 1970-09-30 | 1973-02-07 | ||
| HU172937B (en) * | 1975-12-18 | 1979-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing chondroitinsulphuric acid derivatives with local anaesthetic activity |
| US4302577A (en) * | 1979-10-05 | 1981-11-24 | Biomed Research Inc. | Process for preparing CSA or CSC |
-
1982
- 1982-06-30 EP EP82902411A patent/EP0083367A1/en not_active Withdrawn
- 1982-06-30 AU AU87629/82A patent/AU8762982A/en not_active Abandoned
- 1982-06-30 US US06/479,865 patent/US4489065A/en not_active Expired - Lifetime
- 1982-06-30 WO PCT/US1982/000879 patent/WO1983000150A1/en unknown
- 1982-06-30 CA CA000406418A patent/CA1188988A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| US4489065A (en) | 1984-12-18 |
| WO1983000150A1 (en) | 1983-01-20 |
| EP0083367A1 (en) | 1983-07-13 |
| AU8762982A (en) | 1983-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1188988A (en) | Chondroitin drug complexes | |
| US4585754A (en) | Stabilization of proteins and peptides by chemical binding with chondroitin | |
| US5622718A (en) | Alginate-bioactive agent conjugates | |
| US5688931A (en) | Polysaccharide derivatives and drug carriers | |
| RU2016567C1 (en) | Process for manufacturing medicinal preparation capable of producing antiviral effect | |
| DE69734607T2 (en) | LONG-ACTING MEDICAMENTS AND MEDICAMENTS CONTAINING THEM | |
| CA1291123C (en) | Heavy metal salts of hyaluronic acid useful as antimicrobial agents | |
| US3939270A (en) | Pharmaceutical preparations containing α-aminopenicillins | |
| CS207742B2 (en) | Method of makingthe inclusion complex of the cyclodextrin and acid 1-/p-chlorbenzoyl/-5-methoxy-2-methylind-3-yl-vinegar | |
| HU185223B (en) | Process for preparing an enzymatic derivative containing a binary complex of streptokynase and plasminogen | |
| JPH0662634B2 (en) | Therapeutically active compound | |
| CA2018833A1 (en) | Polymer/antibiotic conjugate | |
| US8492352B2 (en) | Polysaccharides with antithrombotic activity, including a covalent bond and an amino chain | |
| JP4018181B2 (en) | Glycosaminoglycan derivative and process for producing the same | |
| DE69917281T2 (en) | COUMARIN AND RELATED AROMATIC POLYMER PRODRUGS | |
| EP0019403B1 (en) | Hydroxyalkyl-starch drug carrier | |
| US3843787A (en) | Water soluble derivative of erythromycin | |
| US4623718A (en) | Novel composition of matter of antithrombin III bound to a heparin fragment | |
| CA1114812A (en) | Hapten polysaccharide conjugates | |
| EP0344068B1 (en) | N-polyosyl-polypeptides | |
| US20060166927A1 (en) | Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same | |
| US3843626A (en) | Anti-inflammatory compositions containing acylated-b-d-glucopyranosides and methods of using them | |
| JP3018046B2 (en) | A new dextran-derived antitumor substance | |
| EP0242416B1 (en) | Method of protein stabilization | |
| RU2073016C1 (en) | Method of low-molecular water-soluble chitosan preparing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |